Alfasigma today unveiled Morpho, the new brand identity of its Contract Development and Manufacturing Organization (CDMO) Business Unit. This announcement was made at CPHI 2024, the most important event in the pharmaceutical sector, specifically for Contract Development and Contract Manufacturing, taking place in Milan from October 8 to 10.
Established in 2017, the CDMO Business Unit has demonstrated steady growth in recent years (with a double-digit CAGR), its success is built upon Alfasigma's decades-long expertise in providing third-party development and manufacturing services for pharmaceuticals.
Rocco Paracchini, Director of Alfasigma's CDMO Business Unit, explains: “The new brand identity Morpho, which in ancient Greek means ‘to give form’ or to shape, arises from a specific need: to narrate the growth of the Business Unit, leveraging its ability to constantly renew itself and consolidate its leadership acquired over the years in the market.”
With over 60 years of experience, Alfasigma's Contract Manufacturing service continues to invest in process innovation and skills to find the optimal solution for every new challenge. The CDMO Business Unit operates at pharmaceutical facilities in Pomezia (RM), Alanno (PE), Trezzano Rosa (MI), Shreveport (USA), and Sermoneta (LT, Biosint), boasting a team of experts and state-of-the-art technologies to bring high-quality pharmaceutical products to life.
Alfasigma's CDMO offers versatility and product diversification through a wide range of pharmaceutical forms, including liquid injectables (sterilized and aseptic vials and ampoules, pre-filled syringes and cartridges), lyophilized products in vials and ampoules, and sterile powders. The range also includes vaccines and sterile hormonal products to meet specific customer needs.
The sterile departments at the Alanno facility and expertise in sterile filling make Alfasigma a reliable partner for companies in the sector. Its production capabilities also include semi-solids, non-sterile liquids, pressurized foams, and oral solids. Additionally, Alfasigma provides production support services, including, but not limited to, formulation studies, setting up batches for technical and clinical trials, and process validation.
“The Italian pharmaceutical sector is one of the most attractive markets in the EU and ranks among the top five in terms of revenue. [1]In 2023, the Italian CDMO market recorded revenues of 2.3 billion euros, confirming our country’s leadership in this strategic sector,” explains Fabio Russo, Chief Technical Operations Officer of Alfasigma. “It is in this context that investment is focused in our CDMO, which today becomes Morpho and takes on a new identity. The goal is to leverage the reputation that the business unit has earned in recent years as a springboard to further enhance our capabilities. We believe our expertise will make a difference for partners and clients, helping Morpho establish its position at the top of the European CDMO landscape.”
[1] chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://efpia.eu/media/rm4kzdlx/the-pharmaceutical-industry-in-figures-2023.pdf